摘要
目的:观察赫赛汀治疗人表皮生长因子受体2(Her-2)过表达的晚期胃肠道肿瘤的临床疗效。方法:赫赛汀联合化疗治疗11例免疫组化法检测Her-2过度表达的晚期胃肠道肿瘤患者。结果:有效率81.82%(9/11)。TTP最短5.6个月,最长14个月,中位TTP8.6个月。生存时间最长44.5个月(系复治,应用Herceptin联合化疗治疗后生存时间23个月),最短3个月,4例死亡(4/11),中位生存期尚未达到。结论:赫赛汀联合化疗治疗Her-2过表达的晚期胃肠道肿瘤能提高疗效。
Objective： To investigate the effects of herceptin on over-expression of Her-2 in patients with advanced gastrointestinal carcinoma. Methods ： Over-expression of Her-2 was detected in 11 patients with advanced gastrointestinal carcinoma using the immunohistochemical method. All the patients received herceptin combined with chemotherapy. Results： The effective rate of herceptin for patients with advanced gastrointestinal carcinoma was 81.82% （9/11）. The time of tumor progression （T＇FP） was from 5.6months to 14months. The median TIP was 8.6months. Four patients died. The longest survival time of patients was 44.5months and the shortest survival time of patients was 3 months after treatment with herceptin. The median survival time was not evaluated. Conclusion： Herceptin in combination with chemotherapy is effective against over-expression of Her-2 in patients with advanced gastrointestinal carcinoma and may increase the response of patients to chemotherapy.
出处
《军医进修学院学报》
CAS
2009年第3期334-335,共2页
Academic Journal of Pla Postgraduate Medical School
关键词
胃肠道
肿瘤
表皮生长因子受体2
赫赛汀
抗肿瘤联合化疗方案
gastrointestinal tract
neoplasms
receptor, epidermal growth factor
herceptin
antineoplastic combined chemotherapy protocols
